Why Single-Cell Sequencing Has Promise in MDS

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis. The risk of MDS is associated with aging and the accumulation of somatic mutations in hematopoietic stem cells and progenitors (HSPC). While advances in DNA sequencing in the past decade...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuan Zhang, H. Leighton Grimes
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	myelodysplastic syndrome (MDS) single-cell sequencing (SCS) single cell multi-omics profiling hematopoiesis myeloid malignancies Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/24c51db63b734bf88acf61a78e5719f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:24c51db63b734bf88acf61a78e5719f9
record_format	dspace
spelling	oai:doaj.org-article:24c51db63b734bf88acf61a78e5719f92021-12-02T11:04:49ZWhy Single-Cell Sequencing Has Promise in MDS2234-943X10.3389/fonc.2021.769753https://doaj.org/article/24c51db63b734bf88acf61a78e5719f92021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.769753/fullhttps://doaj.org/toc/2234-943XMyelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis. The risk of MDS is associated with aging and the accumulation of somatic mutations in hematopoietic stem cells and progenitors (HSPC). While advances in DNA sequencing in the past decade unveiled clonal selection driven by mutations in MDS, it is unclear at which stage the HSPCs are trapped or what prevents mature cells output. Single-cell-sequencing techniques in recent years have revolutionized our understanding of normal hematopoiesis by identifying the transitional cell states between classical hematopoietic hierarchy stages, and most importantly the biological activities behind cell differentiation and lineage commitment. Emerging studies have adapted these powerful tools to investigate normal hematopoiesis as well as the clonal heterogeneity in myeloid malignancies and provide a progressive description of disease pathogenesis. This review summarizes the potential of growing single-cell-sequencing techniques, the evolving efforts to elucidate hematopoiesis in physiological conditions and MDS at single-cell resolution, and discuss how they may fill the gaps in our current understanding of MDS biology.Xuan ZhangH. Leighton GrimesH. Leighton GrimesH. Leighton GrimesFrontiers Media S.A.articlemyelodysplastic syndrome (MDS)single-cell sequencing (SCS)single cell multi-omics profilinghematopoiesismyeloid malignanciesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	myelodysplastic syndrome (MDS) single-cell sequencing (SCS) single cell multi-omics profiling hematopoiesis myeloid malignancies Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	myelodysplastic syndrome (MDS) single-cell sequencing (SCS) single cell multi-omics profiling hematopoiesis myeloid malignancies Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xuan Zhang H. Leighton Grimes H. Leighton Grimes H. Leighton Grimes Why Single-Cell Sequencing Has Promise in MDS
description	Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis. The risk of MDS is associated with aging and the accumulation of somatic mutations in hematopoietic stem cells and progenitors (HSPC). While advances in DNA sequencing in the past decade unveiled clonal selection driven by mutations in MDS, it is unclear at which stage the HSPCs are trapped or what prevents mature cells output. Single-cell-sequencing techniques in recent years have revolutionized our understanding of normal hematopoiesis by identifying the transitional cell states between classical hematopoietic hierarchy stages, and most importantly the biological activities behind cell differentiation and lineage commitment. Emerging studies have adapted these powerful tools to investigate normal hematopoiesis as well as the clonal heterogeneity in myeloid malignancies and provide a progressive description of disease pathogenesis. This review summarizes the potential of growing single-cell-sequencing techniques, the evolving efforts to elucidate hematopoiesis in physiological conditions and MDS at single-cell resolution, and discuss how they may fill the gaps in our current understanding of MDS biology.
format	article
author	Xuan Zhang H. Leighton Grimes H. Leighton Grimes H. Leighton Grimes
author_facet	Xuan Zhang H. Leighton Grimes H. Leighton Grimes H. Leighton Grimes
author_sort	Xuan Zhang
title	Why Single-Cell Sequencing Has Promise in MDS
title_short	Why Single-Cell Sequencing Has Promise in MDS
title_full	Why Single-Cell Sequencing Has Promise in MDS
title_fullStr	Why Single-Cell Sequencing Has Promise in MDS
title_full_unstemmed	Why Single-Cell Sequencing Has Promise in MDS
title_sort	why single-cell sequencing has promise in mds
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/24c51db63b734bf88acf61a78e5719f9
work_keys_str_mv	AT xuanzhang whysinglecellsequencinghaspromiseinmds AT hleightongrimes whysinglecellsequencinghaspromiseinmds AT hleightongrimes whysinglecellsequencinghaspromiseinmds AT hleightongrimes whysinglecellsequencinghaspromiseinmds
_version_	1718396279583670272

Why Single-Cell Sequencing Has Promise in MDS

Ejemplares similares